rc48-adc
Recurrent Uterine Corpus Carcinosarcoma
Floor Backes, MDantibody_drug_conjugateEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Uterine Corpus Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Floor Backes, MD | Early Phase 1 | C |
Carboplatin Floor Backes, MD | Early Phase 1 | C |
Pyrotinib Floor Backes, MD | Early Phase 1 | C |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →